Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. - Wikidata - wikimedia - TriplyDB

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

http://www.wikidata.org/entity/Q33558105

about

Connections between TET proteins and aberrant DNA modification in cancer Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.Clonal evolution in myelodysplastic syndromes Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Whole-exome and targeted sequencing identify ROBO1 and ROBO2 mutations as progression-related drivers in myelodysplastic syndromes.The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy.TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.Addressing heterogeneity of individual blood cancers: the need for single cell analysis.Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.Only SETBP1 hotspot mutations are associated with refractory disease in myeloid malignancies.IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.

P2860

Q26865671-F765E1E0-ECA6-46F5-85B3-6B2BEC0A5407 Q33769072-11490EDC-7498-432E-8E37-E1C973FFE2D9 Q34555597-66D20116-6429-4D89-9FA2-DE401B43CCDF Q36240610-748D5171-35D6-41CD-A89E-4FCB4DB37CCA Q36360964-2A499A51-A8F9-4AF6-9BC4-2483EFE3C8F6 Q36364763-7FBD5640-AB60-4C39-9730-59DAC56BB265 Q36946728-6A901DFE-412A-40C3-A9BB-8D75CA8154AE Q38225750-05EBE0CA-BE48-4C3B-95D4-F5FEA9A80AD5 Q38231548-907F27FD-D7A0-45F4-A1AE-01E7E393F665 Q38808876-A5457661-E7C0-4E67-A34C-74FE58647589 Q47130430-F81666DB-9E7C-4335-9E95-EA60F6561AAD Q47797877-1DB3BE83-9809-4F90-98BA-AF5118DDAAB1 Q48595265-A24D9ED8-D0E1-47B0-8AAE-DE8B1E3B0DD7

P2860

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

http://www.wikidata.org/entity/Q33558105

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@ast

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@en

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@nl

type

label

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@ast

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@en

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@nl

prefLabel

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@ast

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@en

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@nl

P1433

Q33558105-0FB48563-AE15-49FA-9BC4-373DE4280DB6

P1476

Q33558105-6A933897-E0BF-4C6D-907F-C3F88B0346A8

P2093

Q33558105-17A3943E-AEA8-4A91-A658-7B5F252EFF13

Q33558105-1D68C6A0-3F77-40E6-8D4E-28E819C6908B

Q33558105-1F8CEB5A-FED9-4034-8161-0E25077CDF93

Q33558105-39FB3345-1B3C-4B65-BC5C-4CDBB22FF68B

Q33558105-46904336-9D7C-4DD5-95D1-29290DB7F6D9

Q33558105-4D2CFD4B-0A35-4B24-BD63-7AFBF3587504

Q33558105-62E5C932-FC3D-4B42-AD7C-7EBCCBB407B0

Q33558105-8FDAA496-96FD-4E22-9CCF-81EA9AD6C2CB

Q33558105-91A39C08-3E08-41AA-AD45-8ED9BB617460

Q33558105-935FC445-58C7-451C-8E6A-93A666D3CC08

P2860

Q33558105-061E0F27-022B-46E2-A11F-4E98D7501E33

Q33558105-1F72C141-8AE3-418A-8830-24BD3082D2D5

Q33558105-207969BE-A520-4B16-8BBD-D9443FB6248F

Q33558105-2544E2F7-0C8C-4DBF-AFB9-934CAC587F2F

Q33558105-29335382-0067-43CE-AD05-BE3684858D86

Q33558105-2CDA8160-D9F7-41E4-BCFE-C2AF9075D938

Q33558105-2CFB945D-3A7A-4369-9DE6-E597768A4774

Q33558105-2F38D8B6-CD36-4265-8C13-065443E97455

Q33558105-31A66FAD-A24E-4A9A-9675-A5DE5E80E612

Q33558105-3299D21D-7BC4-433F-BB5C-C2B370F722A1

P304

Q33558105-7DC1FA37-8452-441F-9E74-F8CFE85889E1

P31

Q33558105-54EB09AD-07B1-4135-B8B5-7895D49026F7

P356

Q33558105-EB2A2EF5-451A-4514-A6B7-0CC914DE4DA8

P433

Q33558105-3F9DBD4A-0A22-4AD1-B139-04B9C405D9B3

P478

Q33558105-6C5D3DBB-6CDA-4F31-BCA2-A9AA5F215963

P50

Q33558105-6A7B5DB6-4AFE-4179-B78B-E913441B84F9

P577

Q33558105-DF1A33F1-7474-45BD-9D44-38488907E91F

P698

Q33558105-FFEE2D3D-CCF3-46CC-AF2F-9C57E7F38445

P921

Q33558105-F9D53C3B-63E5-43E5-AC93-BFCA7AAAF541

P932

Q33558105-F2187B57-477C-40A8-979E-1FD26B420EB9

P356

HAEMATOL.2013.091249

P1433

P1476

Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.

@en

P2093

Chang-Liang Lai

http://www.w3.org/2001/XMLSchema#string

Chein-Fuang Huang

http://www.w3.org/2001/XMLSchema#string

Der-Cherng Liang

http://www.w3.org/2001/XMLSchema#string

En-Hui Lee

http://www.w3.org/2001/XMLSchema#string

Hiroko Tanaka

http://www.w3.org/2001/XMLSchema#string

Hsiao-Wen Kao

http://www.w3.org/2001/XMLSchema#string

Jin-Hou Wu

http://www.w3.org/2001/XMLSchema#string

Kenichi Chiba

http://www.w3.org/2001/XMLSchema#string

Lee-Yung Shih

http://www.w3.org/2001/XMLSchema#string

Masashi Sanada

http://www.w3.org/2001/XMLSchema#string

P2860

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases

DNMT3A Mutations in Acute Myeloid Leukemia

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.

Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

P304

28-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2013.091249

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23996483

http://www.w3.org/2001/XMLSchema#string

P921

P932

4007920

http://www.w3.org/2001/XMLSchema#string